

DOCKET NO.: 0769-0420-0X PCT




RECEIVED

JUN 14 2001

TECH CENTER 1600/2900

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231



ATTORNEYS AT LAW

NORMAN F. OBLON
(703) 413-3000
NOBLON@OBLON.COM

KIRSTEN A. GRUENEBERG, PH. D.
(703) 413-3000
KGGRUENEBERG@OBLON.COM

Re: Serial No.: 09/530,965
Date Filed: MAY 18, 2000
Applicants: Martha A. WARPEHOSKI, et al.
For: ALPHA-HYDROXY, -AMINO AND
-FLUORO DERIVATIVES OF BETA-
SULPHONYL HYDROXAMIC ACIDS AS
MATRIX METALLOPROTEINASES
INHIBITORS
Examiner: H. LIU
GAU: 1624

SIR:

Attached hereto for filing are the following papers:

1. RESPONSE TO RESTRICTION REQUIREMENT

Our check in the amount of \$ -0- is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 C.F.R. §1.136 for any necessary Extension of Time to make the filing of the attached documents timely, please charge or credit the difference to our Deposit Account No. 15-0030. Further, if these papers are not considered timely filed, then a petition is hereby made under 37 C.F.R. §1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.



Norman F. Oblon
Attorney of Record
Registration No. 24,618

Kirsten A. Grueneberg, Ph.D.
Registration No. 47,297

Tel.: 703-413-3000
Fax: 703-413-2220

NFO:KAG:ksh
I:\user\KGRUN\07690420-ShrtCvr.wpd



22850

1755 JEFFERSON DAVIS HIGHWAY ■ FOURTH FLOOR ■ ARLINGTON, VIRGINIA 22202 ■ U.S.A.
TELEPHONE: 703-413-3000 ■ FACSIMILE: 703-413-2220 ■ WWW.OBLON.COM

RECEIVED

JUN 14 2001

TECH CENTER 1600/2900



DOCKET NO.: 0769-0420-0X PCT

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

#8

IN RE APPLICATION OF:

MARTHA A. WARPEHOSKI ET AL : GROUP ART UNIT: 1624

SERIAL NO.: 09/530,965 :

FILED: MAY 18, 2001 : EXAMINER: H. LIU

FOR: ALPHA-HYDROXY,-AMINO AND
-FLUORO DERIVATIVES OF BETA-
SULPHONYL HYDROXAMIC ACIDS AS
MATRIX METALLOPROTEINASES INHIBITORS

RESPONSE TO RESTRICTION REQUIREMENT

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

SIR:

Responsive to the Official Action dated May 11, 2001, Applicants elect, with
traverse, Group II, Claims 4 and 6, for further prosecution.

REMARKS

The Office has required restriction in the present application as follows:

Group I: Claims 1-3, 5 and 7-19, drawn to the compounds of formula I, their
compositions, and methods of use of the compounds; and

Group II: Claims 4 and 6, drawn to the compounds of formula 8.

Applicants elect, with traverse, Group II, Claim 4 and 6, for further prosecution.

The Examiner, citing PCT Rule 13.1 and 13.2, contends that Groups I-II do not relate
to a single general inventive concept because they lack the same or corresponding special
technical features. Specifically, the Office argues that the application lacks unity of